Elsevier

Genetics in Medicine

Volume 13, Issue 11, November 2011, Pages 956-965
Genetics in Medicine

Article
Clinical utility of family history for cancer screening and referral in primary care: A report from the Family Healthware Impact Trial

https://doi.org/10.1097/GIM.0b013e3182241d88Get rights and content
Under an Elsevier user license
open archive

Abstract

Purpose

To assess the effectiveness of computerized familial risk assessment and tailored messages for identifying individuals for targeted cancer prevention strategies and motivating behavior change.

Methods

We conducted a randomized clinical trial in primary care patients aged 35–65 years using Family Healthware, a self-administered, internet-based tool that collects family history for six common diseases including breast cancer, colon cancer, and ovarian cancer, stratifies risk into three tiers, and provides tailored prevention messages. Cancer screening adherence and consultation were measured at baseline and 6-month follow-up.

Results

Of 3283 participants, 34% were at strong or moderate risk of at least one of the cancers. Family Healthware identified additional participants for whom earlier screening (colon cancer, 4.4%; breast cancer, women ages: 35–39 years, 9%) or genetic assessment (colon cancer, 2.5%; breast cancer, 10%; and ovarian cancer, 4%) may be indicated. Fewer than half were already adherent with risk-based screening. Screening adherence improved for all risk categories with no difference between intervention and control groups. Consultation with specialists did not differ between groups.

Conclusion

Family Healthware identified patients for intensified cancer prevention. Engagement of clinicians and patients, integration with clinical decision support, and inclusion of nonfamilial risk factors may be necessary to achieve the full potential of computerized risk assessment.

Keywords

family history
risk assessment
early detection of cancer
neoplasms
health knowledge
attitudes
practice

Cited by (0)

Disclosure: The authors declare no conflict of interest.